Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Sharp HealthCare.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Geoffrey Weinstein, M.D., Sharp Memorial Hospital Identifier:
First received: February 23, 2012
Last updated: March 9, 2012
Last verified: March 2012

February 23, 2012
March 9, 2012
January 2011
December 2013   (final data collection date for primary outcome measure)
acute and late toxicity to the GU and GI systems [ Time Frame: 1 year follow-up ] [ Designated as safety issue: Yes ]
acute and late toxicity to the GU and GI systems based on the RTOG definitions will be compared to those of standard radiation therapy.
Same as current
Complete list of historical versions of study NCT01540994 on Archive Site
Drop in the PSA (biochemical marker) [ Time Frame: 1 year follow-up ] [ Designated as safety issue: No ]
One year biochemical control rate of >90%.
Same as current
Not Provided
Not Provided
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate

The purpose of this study is to evaluate a short course (five radiation treatments) of very focused ("stereotactic") external beam radiation therapy for the treatment of early stage prostate cancer.

External beam radiation therapy for prostate cancer, while effective, takes up to 9 weeks to deliver on a Monday through Friday basis. Recent phase I/II studies from Seattle and Palo Alto using stereotactic guidance to deliver high doses of radiation to the prostate over a 1 to 2 week period of time suggest that outcomes may be equal or superior to standard approaches. These data, combined with markedly improved convenience for patients, make radiosurgery (SBRT) for early-stage prostate cancer an enticing option. The goal of this study is to offer a radiosurgical option to patients within the Sharp system under the umbrella of an IRB-approved study.

Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostatic Neoplasm
Radiation: radiation therapy
Stereotactic Body Radiation Therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male with any age (typically 50 to 70 years old) with a low risk disease. This is defined as a Gleason's score of 6 or less, clinical stage of T2a or less, and a PSA of less than 10. We will also include patients with Gleason's score of 3+4=7 if there are fewer than 2 cores positive, with no more than 5mm of tumor in aggregate dimension.

Exclusion Criteria:

  • Prior surgery or radiotherapy for prostate cancer, PSA over 10, Gleason scores 7, 8, 9, or 10 (except Gleason 7 as noted, above), or clinical stage T2b, T2c, T3, or T4.
50 Years to 90 Years
Contact: Geoffrey Weinstein, M.D. 858-939-5010
United States
Geoffrey Weinstein, M.D., Sharp Memorial Hospital
Sharp HealthCare
Not Provided
Principal Investigator: Geoffrey Weinstein, M.D. Sharp HealthCare
Sharp HealthCare
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP